Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Ptc Therapeutics (PTCT) over the last 12 years, with Q2 2025 value amounting to $286.0 million.

  • Ptc Therapeutics' Non-Current Debt rose 42.38% to $286.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $286.0 million, marking a year-over-year increase of 42.38%. This contributed to the annual value of $285.4 million for FY2024, which is 42.19% up from last year.
  • Per Ptc Therapeutics' latest filing, its Non-Current Debt stood at $286.0 million for Q2 2025, which was up 42.38% from $285.7 million recorded in Q1 2025.
  • Over the past 5 years, Ptc Therapeutics' Non-Current Debt peaked at $573.2 million during Q3 2023, and registered a low of $281.6 million during Q3 2021.
  • Over the past 5 years, Ptc Therapeutics' median Non-Current Debt value was $285.3 million (recorded in 2024), while the average stood at $364.3 million.
  • In the last 5 years, Ptc Therapeutics' Non-Current Debt soared by 10281.45% in 2022 and then tumbled by 5028.83% in 2023.
  • Over the past 5 years, Ptc Therapeutics' Non-Current Debt (Quarter) stood at $281.9 million in 2021, then skyrocketed by 102.81% to $571.7 million in 2022, then tumbled by 50.29% to $284.2 million in 2023, then rose by 0.42% to $285.4 million in 2024, then rose by 0.21% to $286.0 million in 2025.
  • Its last three reported values are $286.0 million in Q2 2025, $285.7 million for Q1 2025, and $285.4 million during Q4 2024.